NCT01103804

Brief Summary

The primary objective of the study is to describe the change in GerdQ sum scores, after a 4-week period of systematic treatment with PPIs(using GerdQ questionnaire). The secondary objectives are: to measure the response at the current treatment after a 4-week period of systematic treatment and to identify the percentage of patients which require alterations of their treatment (GerdQ questionnaire)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
952

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2010

Shorter than P25 for all trials

Geographic Reach
1 country

19 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2010

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 13, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 15, 2010

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2010

Completed
Last Updated

January 11, 2011

Status Verified

January 1, 2011

Enrollment Period

6 months

First QC Date

April 13, 2010

Last Update Submit

January 10, 2011

Conditions

Keywords

GerdQ questionnaire

Outcome Measures

Primary Outcomes (1)

  • describe the change in GerdQ sum scores, after a 4-week period of systematic treatment with PPIs(GerdQ)

    4 weeks(at V1 and V2)

Secondary Outcomes (2)

  • measure the response at the current treatment after a 4-week period of systematic treatment with PPIs(GerdQ)

    4 weeks(at V1 and V2)

  • identify the percentage of patients which require alterations of their treatment after a 4-week period of systematic treatment with PPIs(GerdQ)

    4 weeks(at V1 and V2)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study population are patients known/newly diagnosed with GERD or with symptoms suggesting GERD( hearburn, regurgitations) who presented to their family physician(primary care clinic)

You may qualify if:

  • Provision of informed consent
  • Patients known or newly diagnosed with GERD or patients with typical symptoms of GERD- heartburn, regurgitation (in the last case, GerdQ sum score should be ≥8, in the absence of PPI treatment)

You may not qualify if:

  • Any symptoms at visit 1 suggesting a need for further investigation, judged by the Investigator (alarm symptoms).The alarm symptoms suggesting complicated disease are: dysphagia, odynophagia, bleeding, weight loss without intention or anemia.
  • Previous participation in the present study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (19)

Research Site

Arad, Romania

Location

Research Site

Bacau, Romania

Location

Research Site

Brasov, Romania

Location

Research Site

Brăila, Romania

Location

Research Site

Bucharest, Romania

Location

Research Site

Buzău, Romania

Location

Research Site

Cluj-Napoca, Romania

Location

Research Site

Floreşti, Romania

Location

Research Site

Galati, Romania

Location

Research Site

Iași, Romania

Location

Research Site

Piteşti, Romania

Location

Research Site

Ploieşti, Romania

Location

Research Site

Rm. Valcea, Romania

Location

Research Site

Sibiu, Romania

Location

Research Site

Slatina, Romania

Location

Research Site

Târgovişte, Romania

Location

Research Site

Tg. Mures, Romania

Location

Research Site

Timișoara, Romania

Location

Research Site

Vanatori(GL), Romania

Location

MeSH Terms

Conditions

Gastroesophageal Reflux

Condition Hierarchy (Ancestors)

Esophageal Motility DisordersDeglutition DisordersEsophageal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Officials

  • CRISTINA TEODORESCU

    AstraZeneca Pharma SRL Romania

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

April 13, 2010

First Posted

April 15, 2010

Study Start

March 1, 2010

Primary Completion

September 1, 2010

Study Completion

September 1, 2010

Last Updated

January 11, 2011

Record last verified: 2011-01

Locations